Olezarsen indicated as an adjunct to diet
— Olezarsen indicated as an adjunct to diet
by Nicole Lou, Senior Staff Writer, MedPage Today
June 24, 2026
• 2 min read
The FDA approved olezarsen (Tryngolza) to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia, the agency announced on Wednesday.
FDA approves Tryngolza to reduce triglycerides, pancreatitis risk in hypertriglyceridemia
TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)
Ionis Climbs As FDA Clears New Therapy To Lower Triglycerides, Pancreatitis Risk - Ionis Pharmaceuticals
Ionis wins FDA label expansion for potential blockbuster triglycerides indication
Ionis scores transformational FDA label expansion for Tryngolza
Elecoglipron, an oral daily GLP-1, confers glucose, weight reduction in phase 2 studies
GLP-1s may lower risk for replacement surgery in knee osteoarthritis
Strange Side Effect Found Among Ozempic Users—and It Has to Do With Smell and Taste
